- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
673
Companies which are more than 50% undervalued based on analyst price target.
673 companies
Disc Medicine
Market Cap: US$2.1b
A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
IRON
US$61.40
7D
2.7%
1Y
23.8%
CG Oncology
Market Cap: US$2.0b
A late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
CGON
US$27.46
7D
1.6%
1Y
-22.4%
Vitrolife
Market Cap: SEK 18.2b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
VITR
SEK 133.70
7D
-0.4%
1Y
-46.8%
Dyne Therapeutics
Market Cap: US$1.9b
A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
DYN
US$13.50
7D
0.9%
1Y
-57.7%
Vericel
Market Cap: US$1.8b
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
VCEL
US$34.60
7D
-5.1%
1Y
-29.4%
Ascletis Pharma
Market Cap: HK$14.0b
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China.
1672
HK$14.10
7D
6.4%
1Y
1,310.0%
Gerresheimer
Market Cap: €1.5b
Provides medicine packaging, drug delivery devices, and solutions in Germany and internationally.
GXI
€43.44
7D
2.7%
1Y
-57.9%
BioCryst Pharmaceuticals
Market Cap: US$1.7b
A biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
BCRX
US$8.29
7D
-3.4%
1Y
0.5%
Cogent Biosciences
Market Cap: US$1.7b
A biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$12.00
7D
-1.9%
1Y
9.6%
Trulieve Cannabis
Market Cap: CA$2.3b
Operates as a cannabis retailer.
TRUL
CA$11.36
7D
-8.3%
1Y
-10.9%
Lotus Pharmaceutical
Market Cap: NT$50.8b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$193.00
7D
-1.8%
1Y
-29.6%
Biohaven
Market Cap: US$1.6b
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.
BHVN
US$15.89
7D
1.0%
1Y
-58.4%
Twist Bioscience
Market Cap: US$1.6b
Manufactures and sells synthetic DNA-based products.
TWST
US$26.24
7D
-5.3%
1Y
-35.9%
Immunocore Holdings
Market Cap: US$1.6b
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
IMCR
US$32.26
7D
-1.1%
1Y
-10.6%
Mesoblast
Market Cap: AU$2.5b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$1.94
7D
-22.1%
1Y
95.0%
Travere Therapeutics
Market Cap: US$1.6b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$18.15
7D
4.1%
1Y
80.6%
Beam Therapeutics
Market Cap: US$1.6b
A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
BEAM
US$16.31
7D
-2.0%
1Y
-33.2%
Shanghai Haohai Biological Technology
Market Cap: HK$12.2b
Shanghai Haohai Biological Technology Co., Ltd.
6826
HK$27.08
7D
-4.0%
1Y
-14.3%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.40
7D
3.2%
1Y
13.7%
Wave Life Sciences
Market Cap: US$1.5b
A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
WVE
US$9.62
7D
-3.5%
1Y
73.3%
Edgewise Therapeutics
Market Cap: US$1.5b
A biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
EWTX
US$14.86
7D
1.8%
1Y
-16.9%
Viridian Therapeutics
Market Cap: US$1.5b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$19.14
7D
2.6%
1Y
32.3%
Celldex Therapeutics
Market Cap: US$1.5b
A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
CLDX
US$22.06
7D
1.4%
1Y
-46.8%
Harrow
Market Cap: US$1.4b
An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
HROW
US$37.72
7D
-2.2%
1Y
-4.8%
Precigen
Market Cap: US$1.4b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.76
7D
3.7%
1Y
393.3%
MannKind
Market Cap: US$1.4b
A biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.
MNKD
US$5.74
7D
41.0%
1Y
-5.6%
Syndax Pharmaceuticals
Market Cap: US$1.4b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$16.12
7D
1.7%
1Y
-21.5%
Vera Therapeutics
Market Cap: US$1.4b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$22.61
7D
0.3%
1Y
-41.1%
Janux Therapeutics
Market Cap: US$1.4b
A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer.
JANX
US$22.86
7D
-3.3%
1Y
-49.2%
PeptiDream
Market Cap: JP¥199.2b
A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
4587
JP¥1,541.50
7D
-2.6%
1Y
-41.0%
89bio
Market Cap: US$1.3b
A clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
ETNB
US$9.19
7D
-1.8%
1Y
4.7%
Innoviva
Market Cap: US$1.3b
Engages in the development and commercialization of pharmaceutical products in the United States and internationally.
INVA
US$20.88
7D
4.8%
1Y
7.0%
AbCellera Biologics
Market Cap: US$1.2b
Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
ABCL
US$4.05
7D
-7.3%
1Y
62.0%
Intellia Therapeutics
Market Cap: US$1.2b
A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
NTLA
US$11.40
7D
0.4%
1Y
-47.3%
Novavax
Market Cap: US$1.2b
A biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.
NVAX
US$7.55
7D
0.7%
1Y
-40.4%
Enliven Therapeutics
Market Cap: US$1.2b
A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
ELVN
US$20.89
7D
2.8%
1Y
-5.9%